For more pictures and videos, see: http://www.multivu.com/players/English/7828151-ibrance/ Kirkland, QC 10th May 2016 / PRNewswire / - Today Pfizer Canada announced that Health Canada has granted conditional approval IBRANCE TM (palbociclib), and is available in Canada. IBRANCE is a kinase inhibitor letrozole in combination for the treatment of postmenopausal women given estrogen-receptor positive factor (ER), human epidermal growth receptor 2 (HER2) -negative breast cancer Advanced based as initial therapy on the endocrine system for metastatic disease. 2 As Terry Playfair, a large - mother was diagnosed 66 years five years, metastatic HER2-negative ER - positive breast cancer (MBC), which was felt discouraged and hopeless. "It was very difficult to know who was with a terminal illness to live that would probably leave me with only a few years to be with my family and friends left," Terry Playfair said. "When I was diagnosed, my doctor m ' has enrolled in a clinical trial IBRANCE. I am excited about the opportunity, a new option to try, and I am pleased that like me, more women are now living available with metastatic breast cancer. " About a diagnosed by three women with breast cancer, metastases 3 is Terry develop not alone in their fight against MBC. In fact, about 5-10 percent of newly diagnosed breast cancers are metastatic and 20-30 percent of women diagnosed with early breast cancer, the MWC life will develop. 4.5, 3 "As someone who works with women living with metastatic breast cancer, and the staff experienced a breast cancer diagnosis, understand the important role of new drugs in the treatment of this disease play," said Cathy Ammendolea, Chief Executive Officer, Canadian Cancer Network. "Women who live with MBC simply not to wait the luxury of time for access to new drugs." "While awareness has increased for the early age of breast cancer, there are still many misconceptions about metastatic disease, patients feel isolated and can rely hopeless," 6 says MJ DeCoteau, founder and executive director, Rethink Breast Cancer. "We need to increase the volume of the conversation on the CMM and the message that this is an incurable form of cancer, new treatments to help women live longer with a good quality of life." Despite improvements in early detection and treatment, there is no cure for MSCC, demonstrates the necessity of investment and research in this area to increase. 7 "Less than one in four women diagnosed with metastatic breast cancer live longer than five years, a stark contrast to breast cancer in the beginning, where nine out of 10 patients survive more than five years at the stage" he said Dr. John Mackey, medical oncologist and Professor at the University of Alberta, and director of translational research in oncology (TRIO), an academic organization for non-profit clinical research (CRO). "Today's announcement is exciting because there are women across Canada with advanced new treatment option for living this incurable but treatable cancer breast." 7 IBRANCE offers patients a new treatment option, while the awareness and dialogue about this often misunderstood and inspired difficult disease.
February 1st
